Title page

Type of manuscript: Research Article

Title: **HCV spontaneous clearers showed low senescence profile in people living with HIV**

SUPPLEMENTARY DATA INDEX

Additional file 1: Multidisciplinary Group of viral coinfection HIV/Hepatitis (COVIHEP)

Hospitals of the multidisciplinary group of HIV/Hepatitis viral coinfection (COVIHEP) that have collaborated in the study [In alphabetical order of institutions and authors within each institution]:

- **12 de octubre University Hospital (Madrid-Spain):** Laura Bermejo-Plaza; Otilia Bisbal; Lourdes Domínguez-Domínguez; María Lagarde; Mariano Matarranz; Federico Pulido; Rafa Rubio; Mireia Santacreu

- **Infanta Leonor University Hospital (Madrid-Spain)**: Guillermo Cuevas; Victorino Diez-Viñas; Pablo Ryan; Jesús Troya.

- **La Paz University Hospital (Madrid-Spain)**: Juan Miguel Castro-Álvarez; Marta Gálvez-Charro; Luz Martín-Carbonero; Mario Mayoral-Muñoz.

- **La Princesa University Hospital (Madrid-Spain)**: Ignacio de los Santos; Lucio García-Fraile; Jesús Sanz-Sanz.

- **Puerta de Hierro University Hospital** (Majadahonda, Spain): Alfonso Ángel-Moreno; Sara de la Fuente Moral

Additional file 2: Senescence-Associated Secretory phenotype (SASP) biomarkers.

Target Name	Full description
EGF	Epidermal Growth Factor
Eotaxin	Eosinophil chemotactic protein
Gro-alpha (CXCL1)	Growth-regulated oncogene-alpha
GM-CSF	Granulocyte Macrophage Colony-Stimulating Factor
IFN gamma	Interferon-gamma
IL-1 beta	Interleukin-1 beta
IL-1 alpha	Interleukin-1 alpha
IL-1RA	Interleukin-1 receptor antagonist
IL-2	Interleukin-2
IL-6	Interleukin-6
IL-7	Interleukin-7
IL-8 (CXCL8)	Interleukin-8
IL-13	Interleukin-13
IL-15	Interleukin-15
IL-18	Interleukin-18
IP-10 (CXCL10)	C-X-C motif chemokine ligand 10
MCP-1 (CCL2)	C-C motif chemokine ligand 2
RANTES (CCL5)	C-C motif chemokine ligand 5
SDF-1 alpha (CXCL12)	Stromal cell-derived factor 1-alpha
FGF-2	Fibroblast growth factor 2
HGF	Hepatocyte growth factor
NGF	Nerve growth factor
PIGF-1	Placental growth factor
PD1	Programmed Death protein 1
PD-L1	Programmed Death-ligand 1
PD-L2	Programmed Death-ligand 2
SCF	Skp, cullin, F-box containing complex
TNF-alpha	Tumor necrosis factor-alpha
TNF-beta	Tumor necrosis factor-beta
TIM-3 (HAVCR2)	Hepatitis A virus cellular receptor 2

Additional file 3: Comparison of biomarkers of cellular senescence between SC and HIV.

	SC (n=36)	HIV (n=35)	p	AMR (CI95%)	p	q	aAMR (CI95%)	p	q
TAC (nmole/µL)	5.23 (4.75-5.57)	4.94 (4.37-6.01)	0.82	0.98 (0.88-1.08)	0.66	0.93	1.00 (0.90-1.11)	0.98	0.98
GSH (µM)	29.10 (26.03-33.73)	29.95 (27.24-35.40)	0.25	0.96 (0.87-1.06)	0.46	0.93	0.92 (0.82-1.02)	0.09	0.83
GSSG (µM)	17.64 (12.19-31.78)	17.08 (13.74-26.35)	0.50	1.23 (0.82-1.83)	0.32	0.93	1.09 (0.70-1.69)	0.70	0.98
GSH/GSSG	1.81 (0.91-2.91)	2.06 (1.11-2.61)	0.95	0.74 (0.47-1.15)	0.18	0.93	0.91 (0.57-1.46)	0.69	0.98
Nitrate (µM)	10.86 (6.70-16.97)	13.30 (9.03-20.42)	0.36	0.85 (0.65-1.13)	0.26	0.93	0.83 (0.63-1.10)	0.19	0.83
LP (nmole/mL) ($x10^3$)	0.73 (0.58-0.90)	0.85 (0.32-0.99)	0.72	0.98 (0.75-1.30)	0.91	0.93	0.91 (0.68-1.23)	0.54	0.98
PCC (nmole/mg	0.15 (0.07-0.26)	0.14 (0.05-0.28)	0.95	1.05 (0.68-1.62)	0.84	0.93	1.01 (0.64-1.60)	0.96	0.98
DNA damage (pg/mL) ($x10^3$)	3.87 (2.98-5.84)	4.15 (3.01-5.48)	0.91	1.02 (0.82-1.28)	0.85	0.93	1.03 (0.83-1.28)	0.82	0.98
RTL	0.27 (0.23-0.32)	0.29 (0.23-0.32)	0.96	1.01 (0.90-1.13)	0.93	0.93	0.99 (0.89-1.11)	0.91	0.98

Statistics: Values are expressed as median (interquartile range). The AMR values were obtained using a generalized linear model and multivariate analysis was performed with the most significant variables. Abbreviations: SC, PLWHIV who spontaneously clarify HCV; HIV, PLWHIV control group; AMR, arithmetic median ratio; aAMR, adjusted arithmetic median ratio; q, corrected level of significance by false discovery rate; TAC, total antioxidant capacity; GSH, reduced glutathione; GSSG, oxidized glutathione; LP, lipid peroxidation; PCC, protein carbonyl content; RTL, relative telomere length.

Additional file 4: Comparison of senescence-associated secretory phenotype (SASP) between SC and HIV.

	SC (n=36)	HIV (n=35)	p	AMR (CI95%)	p	q	aAMR (CI95%)	p	q
Th1/Th2									
GM-CSF	18.00 (14.24-21.43)	20.26 (15.08-26.75)	0.25	0.91 (0.79-1.05)	0.18	0.47	0.89 (0.78-1.03)	0.11	0.33
IFN-γ	30.84 (24.70-45.49)	28.52 (23.77-55.29)	0.93	0.83 (0.64-1.08)	0.17	0.47	0.85 (0.64-1.12)	0.24	0.47
IL-1β	14.27 (10.85-19.23)	17.75 (14.07-23.80)	**0.04***	0.86 (0.71-1.02)	0.09	0.46	0.87 (0.72-1.04)	0.12	0.33
IL-2	18.00 (14.44-21.91)	19.88 (14.59-25.40)	0.31	0.91 (0.77-1.08)	0.29	0.61	0.89 (0.75-1.06)	0.19	0.45
IL-6	20.25 (15.74-25.88)	23.00 (19.00-27.53)	0.24	0.87 (0.73-1.04)	0.13	0.47	0.87 (0.73-1.04)	0.13	0.33
IL-8	60.00 (52.80-71.80)	60.00 (54.81-75.02)	0.44	0.95 (0.84-1.06)	0.33	0.61	0.94 (0.84-1.06)	0.34	0.55
IL-13	15.73 (13.09-18.62)	17.00 (12.33-21.99)	0.67	0.99 (0.83-1.19)	0.94	0.94	0.93 (0.77-1.12)	0.42	0.58
IL-18	94.55 (64.29-302.68)	94.23 (47.31-241.45)	0.59	0.77 (0.49-1.22)	0.27	0.61	0.79 (0.49-1.27)	0.34	0.55
TNF-α	14.78 (12.50-21.51)	18.59 (15.94-24.62)	**0.02***	0.84 (0.71-0.99)	**0.04***	0.27	0.83 (0.70-0.98)	**0.03***	0.25
Inflammatory cytokines									
IL-1α	49.95 (42.38-61.59)	48.70 (43.49-55.64)	0.65	1.32 (1.06-1.65)	**0.01***	0.20	1.31 (1.04-1.64)	**0.02***	0.25
IL-1RA	30.87 (21.50-44.50)	29.78 (22.09-50.06)	0.92	0.95 (0.70-1.29)	0.74	0.88	0.95 (0.68-1.32)	0.75	0.82
IL-7	20.07 (17.00-22.75)	21.98 (19.00-27.61)	0.09	0.88 (0.79-0.99)	**0.04***	0.27	0.87 (0.77-0.98)	**0.03***	0.25
IL-15	20.00 (17.09-25.39)	22.00 (19.25-27.16)	0.22	0.89 (0.75-1.04)	0.14	0.47	0.87 (0.74-1.03)	0.11	0.33
TNF-β	71.18 (60.93-89.90)	73.88 (59.00-96.85)	0.44	0.92 (0.77-1.10)	0.37	0.61	0.91 (0.75-1.09)	0.29	0.54
Chemokines									
Eotaxin	125.91 (71.53-156.07)	101.70 (59.69-161.30)	0.40	1.04 (0.79-1.38)	0.78	0.88	1.01 (0.76-1.34)	0.94	0.94
Gro-α	48.32 (41.48-57.97)	48.93 (40.50-58.34)	0.93	1.03 (0.91-1.16)	0.66	0.84	1.02 (0.91-1.15)	0.75	0.82
IP-10	114.49 (93.86-146.36)	119.27 (82.72-209.16)	0.61	0.84 (0.65-1.09)	0.18	0.47	0.77 (0.60-0.99)	**0.04***	0.25
MCP-1	129.78 (103.80-206.50)	143.00 (100.06-245.20)	0.53	0.95 (0.75-1.20)	0.65	0.84	0.95 (0.75-1.21)	0.69	0.82
RANTES	6979.61 (5833.00-8804.84)	7793.87 (5862.87-9179.33)	0.39	0.92 (0.76-1.11)	0.37	0.61	0.92 (0.76-1.12)	0.40	0.57
SDF-1α	289.75 (257.77-345.20)	334.766 (303.876-522.206)	0.30	1.06 (0.90-1.25)	0.46	0.67	1.08 (0.91-1.29)	0.36	0.56
Growth factors									
EGF	32.00 (23.50-52.65)	34.58 (22.67-47.88)	0.18	1.06 (0.79-1.43)	0.68	0.84	0.98 (0.74-1.30)	0.89	0.93
FGF-2	39.50 (34.00-43.53)	38.25 (32.01-42.50)	0.62	1.01 (0.91-1.11)	0.90	0.94	0.98 (0.88-1.08)	0.66	0.82
HGF	21.50 (15.00-24.61)	23.50 (16.00-26.33)	0.32	0.93 (0.79-1.11)	0.43	0.66	0.90 (0.76-1.07)	0.24	0.47
NGF	33.80 (29.46-39.00)	33.83 (29.84-39.70)	0.88	0.99 (0.90-1.10)	0.90	0.94	0.98 (0.88-1.09)	0.71	0.82
PIGF-1	262.27 (204.01-312.03)	231.17 (189.54-267.21)	0.24	1.30 (1.05-1.61)	**0.02***	0.20	1.25 (1.00-1.56)	0.05	0.28
SCF	40.00 (34.75-51.50)	40.65 (36.02-50.22)	0.49	0.95 (0.84-1.07)	0.37	0.61	0.91 (0.81-1.02)	0.11	0.33

Statistics: Values are expressed as median of fluorescence (interquartile range). The AMR values were obtained using a generalized linear model and multivariate analysis was performed with the most significant variables. Abbreviations: HIV, PLWHIV control group; SC, PLWHIV who spontaneously clarify HCV; AMR. Arithmetic Median Ratio; aAMR, adjusted Arithmetic Median Ratio; q, corrected level of significance by false discovery rate.

Additional file 5: Comparison of biomarkers of cellular senescence between CHC and HIV.

	CHC (n=45)	HIV (n=35)	p	AMR (CI95%)	p	q	aAMR (CI95%)	p	q
TAC (nmole/µL)	5.01 (4.59-5.94)	4.94 (4.37-6.01)	0.74	1.01 (0.91-1.11)	0.93	0.96	1.03 (0.93-1.14)	0.54	0.66
GSH (µM)	29.29 (28.08-34.61)	29.95 (27.24-35.40)	0.83	0.99 (0.91-1.09)	0.85	0.96	0.97 (0.90-1.07)	0.56	0.66
GSSG (µM)	19.22 (12.32-40.66)	17.08 (13.74-26.35)	0.12	1.42 (0.98-2.06)	0.07	0.30	1.34 (0.90-1.99)	0.15	0.54
GSH/GSSG	1.87 (0.70-2.54)	2.06 (1.11-2.61)	0.12	0.74 (0.47-1.17)	0.20	0.58	0.73 (0.46-1.16)	0.18	0.54
Nitrate (µM)	17.54 (9.90-24.05)	13.30 (9.03-20.42)	0.16	1.34 (1.01-1.77)	**0.04***	0.30	1.40 (1.07-1.84)	**0.02***	0.14
LP (nmole/mL) ($x10^3$)	0.73 (0.43-0.95)	0.85 (0.32-0.99)	0.62	0.94 (0.72-1.24)	0.66	0.96	0.89 (0.67-1.17)	0.38	0.66
PCC (nmole/mg)	0.11 (0.3-0.30)	0.14 (0.05-0.28)	0.42	1.02 (0.63-1.67)	0.93	0.96	1.01 (0.58-1.75)	0.97	0.97
DNA damage (pg/mL) ($x10^3$)	4.57 (2.85-6.05)	4.15 (3.01-5.48)	0.85	0.99 (0.79-1.26)	0.96	0.96	1.09 (0.85-1.40)	0.51	0.66
RTL	0.24 (0.21-0.28)	0.29 (0.23-0.32)	0.09	0.93 (0.82-1.06)	0.26	0.58	0.95 (0.84-1.07)	0.36	0.66

Statistics: Values are expressed as median (interquartile range). The AMR values were obtained using a generalized linear model and multivariate analysis was performed with the most significant variables. Abbreviations: CHC, PLWHIV chronically infected with HCV; HIV, PLWHIV control group; AMR, Arithmetic Median Rate; aAMR, adjusted arithmetic median rate; q, corrected level of significance by false discovery rate; TAC, total antioxidant capacity; GSH, reduced glutathione; GSSG, oxidized glutathione; LP, lipid peroxidation; PCC, protein carbonyl content; RTL, relative telomere length.

Additional file 6: Comparison of senescence-associated secretory phenotype (SASP) between CHC and HIV.

	CHC (n=45)	HIV (n=35)	p	AMR (CI95%)	p	q	aAMR (CI95%)	p	q
Th1/Th2									
GM-CSF	20.39 (16.49-23.77)	20.26 (15.08-26.75)	0.59	1.10 (0.94-1.29)	0.23	0.66	1.14 (0.99-1.33)	0.08	0.25
IFN-γ	37.02 (28.52-62.71)	28.52 (23.77-55.29)	**0.05***	1.07 (0.82-1.39)	0.62	0.74	1.06 (0.81-1.38)	0.69	0.82
IL-1β	17.35 (13.00-22.50)	17.75 (14.07-23.80)	0.78	1.05 (0.87-1.25)	0.63	0.74	1.11 (0.94-1.31)	0.24	0.52
IL-2	19.00 (16.00-23.48)	19.88 (14.59-25.40)	0.94	1.01 (0.86-1.18)	0.95	0.96	1.02 (0.88-1.19)	0.76	0.82
IL-6	20.25 (17.75-23.00)	23.00 (19.00-27.53)	0.26	0.97 (0.81-1.16)	0.74	0.80	0.97 (0.82-1.15)	0.76	0.82
IL-8	64.00 (58.75-73.07)	60.00 (54.81-75.02)	0.21	1.03 (0.94-1.13)	0.53	0.73	1.04 (0.94-1.15)	0.44	0.61
IL-13	17.00 (15.13-21.13)	17.00 (12.33-21.99)	0.49	1.08 (0.91-1.28)	0.37	0.73	1.12 (0.95-1.31)	0.20	0.46
IL-18	131.75 (87.75-322.32)	94.23 (47.31-241.45)	0.10	0.99 (0.65-1.51)	0.96	0.96	0.99 (0.63-1.55)	0.95	0.95
TNF-α	18.59 (14.78-21.25)	18.59 (15.94-24.62)	0.48	1.07 (0.89-1.28)	0.49	0.73	1.09 (0.91-1.29)	0.34	0.56
Inflammatory cytokines									
IL-1α	54.64 (45.20-71.88)	48.70 (43.49-55.64)	**0.04***	1.85 (1.38-2.47)	**<0.001***	**0.02***	1.90 (1.416-2.55)	**<0.001***	**0.02***
IL-1RA	40.04 (24.78-76.45)	29.78 (22.09-50.06)	0.15	1.34 (0.98-1.84)	0.07	0.44	1.35 (0.978-1.86)	0.07	0.25
IL-7	23.50 (20.07-26.63)	21.98 (19.00-27.61)	0.53	1.05 (0.92-1.19)	0.49	0.73	1.07 (0.946-1.21)	0.28	0.53
IL-15	24.29 (20.00-28.70)	22.00 (19.25-27.16)	0.38	1.11 (0.94-1.32)	0.22	0.66	1.16 (0.984-1.36)	0.08	0.25
TNF-β	73.22 (60.93-87.75)	73.88 (59.00-96.85)	0.82	0.95 (0.83-1.10)	0.51	0.73	0.94 (0.820-1.09)	0.43	0.61
Chemokines									
Eotaxin	105.83 (69.65-179.60)	101.70 (59.69-161.30)	0.47	1.08 (0.82-1.43)	0.59	0.74	1.10 (0.85-1.44)	0.47	0.61
Gro-α	50.35 (45.25-58.06)	48.93 (40.50-58.34)	0.30	1.07 (0.97-1.18)	0.17	0.64	1.10 (0.99-1.21)	0.07	0.25
IP-10	187.05 (140.95-297.23)	119.27 (82.72-209.16)	**0.003***	1.39 (1.10-1.76)	**0.007***	**0.06***	1.46 (1.14-1.87)	**0.003***	**0.03***
MCP-1	147.23 (93.80-224.24)	143.00 (100.06-245.20)	0.56	1.11 (0.85-1.45)	0.45	0.73	1.01 (0.79-1.29)	0.93	0.95
RANTES	6766.18 (5601.85-7644.75)	7793.87 (5862.87-9179.33)	0.05	0.90 (0.78-1.0)	0.12	0.51	0.90 (0.78-1.04)	0.14	0.37
SDF-1α	292.60 (257.30-331.69)	334.766 (303.876-522.206)	0.14	1.15 (0.98-1.35)	0.09	0.47	1.17 (0.99-1.38)	0.07	0.25
Growth factors									
EGF	33.00 (23.50-48.19)	34.58 (22.67-47.88)	0.34	1.09 (0.83-1.45)	0.53	0.73	1.06 (0.83-1.37)	0.64	0.79
FGF-2	37.25 (34.52-45.73)	38.25 (32.01-42.50)	0.67	1.05 (0.95-1.15)	0.35	0.73	1.08 (0.99-1.18)	0.10	0.28
HGF	22.50 (16.00-27.50)	23.50 (16.00-26.33)	0.99	1.03 (0.87-1.22)	0.71	0.80	1.07 (0.91-1.27)	0.40	0.60
NGF	35.00 (30.39-39.00)	33.83 (29.84-39.70)	0.68	1.05 (0.95-1.16)	0.35	0.73	1.05 (0.95-1.16)	0.34	0.56
PIGF-1	253.90 (199.18-323.60)	231.17 (189.54-267.21)	0.19	1.35 (1.10-1.65)	**0.004***	**0.05**	1.36 (1.11-1.67)	**0.003***	**0.03***
SCF	42.18 (34.75-51.34)	40.65 (36.02-50.22)	0.78	1.05 (0.94-1.17)	0.36	0.73	1.06 (0.95-1.18)	0.28	0.53

Statistics: Values are expressed as median of fluorescence (interquartile range). The AMR values were obtained using a generalized linear model and multivariate analysis was performed with the most significant variables. Abbreviations: CHC, PLWHIV chronically infected with HCV; HIV, PLWHIV control group; AMR, Arithmetic Median Ratio; aAMR, adjusted Arithmetic Median Ratio; q, corrected level of significance by false discovery rate.

Additional file 7: Comparison of biomarkers of cellular senescence between SC and CHC.

	CHC (n=45)	SC (n=36)	p	AMR (CI95%)	p	q	aAMR (CI95%)	p	q
TAC (nmole/µL)	5.01 (4.59-5.94)	5.23 (4.75-5.57)	0.90	1.03 (0.94-1.13)	0.55	0.96	1.05 (0.95-1.16)	0.33	0.81
GSH (µM)	29.29 (28.08-34.61)	29.10 (26.03-33.73)	0.31	1.03 (0.94-1.13)	0.54	0.96	1.00 (0.90-1.11)	0.95	0.98
GSSG (µM)	19.22 (12.32-40.66)	17.64 (12.19-31.78)	0.48	1.16 (0.80-1.68)	0.44	0.96	0.96 (0.58-1.57)	0.87	0.98
GSH/GSSG	1.87 (0.70-2.54)	1.81 (0.91-2.91)	0.53	1.01 (0.66-1.54)	0.96	0.96	1.19 (0.76-1.87)	0.45	0.81
Nitrate (µM)	17.54 (9.90-24.05)	10.86 (6.70-16.97)	**0.02***	1.57 (1.18-2.10)	**0.002***	**0.02***	1.73 (1.27-2.35)	**<0.001***	**0.008***
LP (nmole/mL) ($x10^3$)	0.73 (0.43-0.95)	0.73 (0.58-0.90)	0.71	0.96 (0.75-1.23)	0.73	0.96	0.91 (0.68-1.23)	0.54	0.81
PCC (nmole/mg	0.11 (0.3-0.30)	0.15 (0.07-0.26)	0.55	0.98 (0.59-1.61)	0.93	0.96	0.77 (0.41-1.43)	0.40	0.81
DNA damage (pg/mL) ($x10^3$)	4.57 (2.85-6.05)	3.87 (2.98-5.84)	0.88	0.97 (0.78-1.22)	0.81	0.96	1.00 (0.78-1.30)	0.98	0.98
RTL	0.24 (0.21-0.28)	0.27 (0.23-0.32)	0.09	0.93 (0.82-1.05)	0.21	0.96	0.91 (0.81-1.03)	0.14	0.65

Statistics: Values are expressed as median (interquartile range). The AMR values were obtained using a generalized linear model and multivariate analysis was performed with the most significant variables. Abbreviations: SC, PLWHIV who spontaneously clarify HCV; CHC, PLWHIV chronically infected with HCV; AMR, Arithmetic Median Rate; aAMR, adjusted Arithmetic Median Rate; q, corrected level of significance by false discovery rate; TAC, total antioxidant capacity; GSH, reduced glutathione; GSSG, oxidized glutathione; LP, lipid peroxidation; PCC, protein carbonyl content; RTL, relative telomere length.

Additional file 8: Comparison of senescence-associated secretory phenotype (SASP) between SC and CHC.

	CHC (n=45)	SC (n=36)	p	AMR (CI95%)	p	q	aAMR (CI95%)	p	q
Th1/Th2									
GM-CSF	20.39 (16.49-23.77)	18.00 (14.24-21.43)	0.25	1.21 (1.04-1.41)	**0.02***	**0.08***	1.30 (1.10-1.52)	**0.002***	**0.01***
IFN-γ	37.02 (28.52-62.71)	30.84 (24.70-45.49)	0.93	1.29 (1.03-1.61)	**0.03***	**0.10***	1.33 (1.05-1.71)	**0.02***	**0.05***
IL-1β	17.35 (13.00-22.50)	14.27 (10.85-19.23)	**0.04***	1.22 (1.01-1.48)	**0.04***	0.12	1.30 (1.07-1.58)	**0.009***	**0.03***
IL-2	19.00 (16.00-23.48)	18.00 (14.44-21.91)	0.31	1.10 (0.94-1.29)	0.24	0.44	1.20 (1.02-1.42)	**0.03***	**0.06***
IL-6	20.25 (17.75-23.00)	20.25 (15.74-25.88)	0.24	1.11 (0.93-1.33)	0.25	0.44	1.18 (0.99-1.41)	0.06	0.11
IL-8	64.00 (58.75-73.07)	60.00 (52.80-71.80)	0.44	1.09 (1.00-1.19)	**0.05***	0.13	1.11 (1.01-1.22)	**0.03***	**0.06***
IL-13	17.00 (15.13-21.13)	15.73 (13.09-18.62)	0.69	1.09 (0.92-1.29)	0.34	0.49	1.21 (1.01-1.44)	**0.04***	**0.08***
IL-18	131.75 (87.75-322.32)	94.55 (64.29-302.68)	0.59	1.28 (0.88-1.85)	0.20	0.42	1.31 (0.86-1.98)	0.21	0.25
TNF-α	18.59 (14.78-21.25)	14.78 (12.50-21.51)	**0.02***	1.27 (1.05-1.54)	**0.02***	**0.08***	1.42 (1.17-1.72)	**<0.001***	**0.006***
Inflammatory cytokines									
IL-1α	54.64 (45.20-71.88)	49.95 (42.38-61.59)	0.65	1.40 (1.01-1.94)	**0.05***	0.13	1.64 (1.16-2.32)	**0.005***	**0.02***
IL-1RA	40.04 (24.78-76.45)	30.87 (21.50-44.50)	0.92	1.41 (1.04-1.92)	**0.03***	**0.10***	1.57 (1.16-2.13)	**0.004***	**0.02***
IL-7	23.50 (20.07-26.63)	20.07 (17.00-22.75)	0.09	1.18 (1.05-1.34)	**0.007***	**0.06***	1.26 (1.10-1.43)	**<0.001***	**0.006***
IL-15	24.29 (20.00-28.70)	20.00 (17.09-25.39)	0.22	1.26 (1.07-1.49)	**0.006***	**0.06***	1.40 (1.18-1.65)	**<0.001***	**0.006***
TNF-β	73.22 (60.93-87.75)	71.18 (60.93-89.90)	0.44	1.03 (0.90-1.19)	0.64	0.76	1.05 (0.90-1.23)	0.54	0.56
Chemokines									
Eotaxin	105.83 (69.65-179.60)	125.91 (71.53-156.07)	0.44	1.04 (0.80-1.35)	0.78	0.82	1.13 (0.87-1.48)	0.37	0.41
Gro-α	50.35 (45.25-58.06)	48.32 (41.48-57.97)	0.93	1.04 (0.94-1.16)	0.44	0.56	1.05 (0.94-1.18)	0.39	0.43
IP-10	187.05 (140.95-297.23)	114.49 (93.86-146.36)	0.61	1.66 (1.33-2.08)	**<0.001***	**0.02***	1.71 (1.34-2.20)	**<0.001***	**0.006***
MCP-1	147.23 (93.80-224.24)	129.78 (103.80-206.50)	0.53	1.17 (0.88-1.56)	0.28	0.45	1.25 (0.94-1.68)	0.13	0.19
RANTES	6766.18 (5601.85-7644.75)	6979.61 (5833.00-8804.84)	0.39	0.98 (0.82-1.16)	0.79	0.82	0.97 (0.80-1.18)	0.79	0.79
SDF-1α	292.60 (257.30-331.69)	289.75 (257.77-345.20)	0.30	1.08 (0.91-1.29)	0.38	0.52	1.13 (0.93-1.38)	0.21	0.25
Growth factors									
EGF	33.00 (23.50-48.19)	32.00 (23.50-52.65)	0.18	1.03 (0.75-1.41)	0.87	0.87	1.26 (0.95-1.68)	0.12	0.19
FGF-2	37.25 (34.52-45.73)	39.50 (34.00-43.53)	0.62	1.04 (0.94-1.14)	0.46	0.56	1.08 (0.98-1.20)	0.12	0.19
HGF	22.50 (16.00-27.50)	21.50 (15.00-24.61)	0.32	1.11 (0.93-1.32)	0.26	0.44	1.20 (0.99-1.45)	0.06	0.11
NGF	35.00 (30.39-39.00)	33.80 (29.46-39.00)	0.88	1.06 (0.95-1.18)	0.33	0.49	1.09 (0.97-1.23)	0.14	0.19
PIGF-1	253.90 (199.18-323.60)	262.27 (204.01-312.03)	0.24	1.04 (0.81-1.33)	0.77	0.82	1.22 (0.94-1.59)	0.14	0.19
SCF	42.18 (34.75-51.34)	40.00 (34.75-51.50)	0.49	1.11 (0.98-1.26)	0.10	0.24	1.17 (1.03-1.34)	**0.02***	**0.05***

Statistics: Values are expressed as median of fluorescence (interquartile range). The AMR values were obtained using a generalized linear model and multivariate analysis was performed with the most significant variables. Abbreviations: SC, PLWHIV who spontaneously clarify HCV; CHC, PLWHIV chronically infected with HCV; AMR, Arithmetic Median Ratio; aAMR. adjusted Arithmetic Median Ratio; q, p-value corrected by false discovery rate.